Novoste Corporation                    Exhibit 11
                        Computation of Net Loss Per Share



                                     Three Months Ended          Nine Months Ended
                                       September  30,             September  30,
                                  ------------------------   ------------------------
                                    1996          1995          1996          1995
                                    ----          ----          ----          ----
                                                                      
Weighted average number of
shares of common stock
outstanding during the year ..    8,086,006     3,833,436     6,002,227     3,574,031

Effect of common stock issued
and stock options and warrants
granted during the 12-month
period preceding April 11,
1996(1) ......................         --       1,194,411       391,767     1,194,411

Elimination of duplicative
effect of including the same
shares in both amounts
above ........................         --        (284,400)     (118,616)     (118,262)
                                -----------   -----------   -----------   -----------

Total common and common
equivalent shares ............    8,086,006     4,743,447     6,275,378     4,650,180
                                ===========   ===========   ===========   ===========

Net loss .....................  ($1,275,813)  ($  746,392)  ($3,759,800)  ($2,251,797)
                                ===========   ===========   ===========   ===========

Net loss per share ...........
    Primary                     ($     0.16)  ($     0.16)  ($     0.60)  ($     0.48)
                                ===========   ===========   ===========   ===========
    Fully Diluted               ($     0.16)  ($     0.16)  ($     0.60)  ($     0.48)
                                ===========   ===========   ===========   ===========


(1)  Pursuant to Securities and Exchange Commission Staff Accounting Bulletin
     No. 83, Common Stock issued and stock options and warrants granted at
     prices below the initial public offering price per share during the
     12-month period immediately preceding the initial filing date of the
     Company's Registration Statement for its initial public offering have been
     included as outstanding for all periods presented which include periods
     prior to such filing date using the treasury stock method.
(2)  Since the impact of including common stock equivalents is anti-dilutive for
     both primary and fully diluted loss per share, the calculation of loss per
     share for both purposes is identical.